Biopharma is poised to lose two of its few female CEOs, GSK’s Emma Walmsley and Merck KGaA’s Belén Garijo, which underscores a troubling trend in an industry where women comprise a majority of the workforce yet remain underrepresented in leadership roles. This situation is exacerbated by systemic barriers that persist despite the growing number of women entering the life sciences sector.
The report identifies four key reasons for this disparity: entrenched biases in hiring practices, a lack of mentorship opportunities, insufficient support for work-life balance, and the prevalence of gender stereotypes that undermine women’s authority. These factors collectively contribute to a leadership landscape that fails to reflect the diversity of the workforce.
The implications are significant for the biopharma industry, as the absence of women in top positions can stifle innovation and limit diverse perspectives in decision-making processes. As companies strive for growth and resilience in a competitive market, addressing these challenges is crucial for fostering a more inclusive environment that leverages the full potential of its workforce.
Start your 7-day trial and see what the database can do →
